Table 3.
Univariate and multivariate analysis of progression free survival in patients with colorectal cancer, treated with melphalan or mitomycin-C as a HIPEC agent.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Characteristics | N | Medial PFS months (95% CI) |
p-value | HR (95% CI) |
p-value |
| Agent | 0.05 | 0.17 | |||
| Melphalan | 18 | 10 (6-13) | 1.62 (0.81-3.27) | ||
| Mitomycin-C∗ | 28 | 24 (9-39) | |||
| Age | 0.36 | 0.89 | |||
| ≤53 years∗ | 32 | 13 (3-23) | |||
| >53years | 14 | 11 (9-11) | 0.95 (0.47-1.96) | ||
| CC score | 0.11 | 0.67 | |||
| CC-0∗ | 38 | 13 (3-23) | |||
| CC-1 | 8 | 12 (10-16) | 1.22 (0.49-3.08) | ||
| PCI | <0.001 | <0.001 | |||
| ≤20∗ | 25 | 28 (18-38) | |||
| >20 | 20 | 10 (4-16) | 4.52 (2.05-9.95) | ||
| LN status | 0.64 | 0.97 | |||
| LN metastases | 19 | 10 (9-12) | 1.01 (0.5-2.07) | ||
| no LN metastases∗ | 23 | 12 (9-15) | |||
HR: hazard ratio; PCI: peritoneal carcinomatosis index; LN: lymph nodes; PFS: progression-free survival; ∗was used as reference in multivariate analysis; Median age of all patients was 53 years.